NewKerala.com

Key Points

Amrutanjan Health Care, a historic Chennai-based pharma giant, reported a notable 21% decline in its Q4 net profits, attributed largely to a sharp increase in expenses. However, the company also posted a revenue increase of over 10%, signaling some operational strengths. Despite the drop in quarterly profits, the Board recommended a substantial dividend for FY25, reassuring investors. On a historical note, the company, founded in 1893, continues to be a significant player in the Ayurvedic health product market.

Key Points: Amrutanjan Health Q4 Profits Dip 21 Amid Rising Expenses

  • Q4 profits drop over 21% to Rs 15.17 crore
  • Expenses rise by 18.05% to Rs 119.37 crore
  • Revenue sees 10.31% increase to Rs 135.41 crore
  • Board recommends Rs 2.60 dividend per share
2 min read

Amrutanjan Health Care's Q4 net profit falls over 21 pc, expenses rise

Amrutanjan Health Care sees Q4 net profits fall by over 21%, impacted by rising expenses and costs.

"The sharp rise in costs appears to have impacted the company's bottom line. - Stock Exchange Filing"

New Delhi, May 15

Chennai-based pharma company, Amrutanjan Health Care Limited, on Thursday reported a decline in its net profit for the fourth quarter ended March 2025 (Q4 FY25), with profit dropping by approximately 21.16 per cent to Rs 15.17 crore, compared to Rs 19.24 crore in the previous quarter (Q3 FY25).

The company's revenue from operations in Q4 stood at Rs 135.41 crore, marking a 10.31 per cent increase from Rs 122.75 crore recorded in Q3, as per its stock exchange filing.

However, total expenses surged by 18.05 per cent, reaching Rs 119.37 crore in Q4, up from Rs 101.12 crore in the previous quarter.

The sharp rise in costs appears to have impacted the company's bottom line.

On year-on-year (YoY) basis, Amrutanjan Health Care's consolidated net profit showed a positive trend, rising by approximately 11.14 per cent from Rs 13.65 crore reported in the March 2024 quarter (Q4 FY24).

The company's Board of Directors has recommended a final dividend of Rs 2.60 per equity share for the financial year 2024-25 (FY25).

This will apply to 2,89,10,630 shares of Re. 1 each, fully paid up.

"If approved at the upcoming Annual General Meeting, the dividend will be distributed to eligible shareholders within 30 days of the meeting," the company said in its stock exchange filing.

In a key leadership change, the company announced that M Srinivasan will retire from his role as Company Secretary and Compliance Officer, effective May 31.

The company also informed the appointment of Gagan Preet Singh as his successor from June 1. The company affirmed that Singh is not debarred from holding office by any regulatory authority.

On the stock market, Amrutanjan Health Care shares closed nearly flat on Thursday, ending at Rs 715 on the National Stock Exchange (NSE), down marginally by Rs 0.40 or 0.06 per cent.

Founded in 1893, Amrutanjan Health Care is known for its Ayurvedic pain relief products and has expanded into various segments such as women's hygiene, cough and cold remedies, and packaged fruit juice drinks.

- IANS

Share this article:

Reader Comments

R
Rajesh K.
Not surprising given how input costs have risen across pharma sector. At least they're maintaining dividend payouts - shows commitment to shareholders. Their pain balm is still my go-to remedy! 🇮🇳
P
Priya M.
Quarterly dip is concerning but YoY growth looks healthy. Hope the new leadership brings fresh energy. Amrutanjan needs to focus more on digital marketing - their social media presence is weak compared to competitors.
A
Arjun S.
Classic case of revenue growth but profit decline. Management should explain what caused 18% expense jump - is it raw materials, salaries or marketing? Transparency matters for long-term investors.
S
Sneha R.
My daadi still swears by their pain relief oil! 😊 But as investor, I'm watching how they balance traditional products with new segments like fruit juices. Diversification is good but shouldn't dilute core brand value.
V
Vikram J.
️Stock market reaction shows investors aren't panicking - flat closing suggests this is seen as temporary blip. At P/E of ~35, still premium valuation for this heritage brand. Long term story intact if they control costs.
N
Neeta B.
Hope the new Company Secretary ensures better cost management. Amrutanjan is part of our healthcare tradition - would hate to see such an iconic brand struggle. Maybe they should leverage their 130+ year legacy more in branding!

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50